Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Ophthalmol. Nov 12, 2013; 3(4): 32-37
Published online Nov 12, 2013. doi: 10.5318/wjo.v3.i4.32
Published online Nov 12, 2013. doi: 10.5318/wjo.v3.i4.32
Melatonin and derivatives as promising tools for glaucoma treatment
Hanan Awad Alkozi, Jesús Pintor, Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, Universidad Complutense de Madrid, E-28037 Madrid, Spain
Author contributions: Alkozi HA and Pintor J contributed equally to this work.
Supported by Universidad Complutense de Madrid, No. GR35/10-A-920777; the Ministry of Economy, No. SAF 2010/16024; the Institute Carlos III, No. RETICS RD12/0034/0003
Correspondence to: Jesús Pintor, Professor, Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, Universidad Complutense de Madrid, c/Arcos de Jalón 118, E-28037 Madrid, Spain. jpintor@ucm.es
Telephone: +34-91-3946859 Fax: +34-91-3946885
Received: August 21, 2013
Revised: November 5, 2013
Accepted: November 10, 2013
Published online: November 12, 2013
Processing time: 120 Days and 18.9 Hours
Revised: November 5, 2013
Accepted: November 10, 2013
Published online: November 12, 2013
Processing time: 120 Days and 18.9 Hours
Core Tip
Core tip: This mini review depicts the main features of melatonin and derivatives as interesting agents for the treatment of the ocular hypertension associated with glaucoma.